Oxford Biomedica, (OXB),...............time to buy.

From today's Citywire (not much but something):



Relevant extract :

"Beeson also highlighted the potential of antibodies as they allow for more accurate targeting, which generally results in a better safety profile than for traditional chemistry–based drugs. Another plus point for antibodies is their production and identification seems to be faster, which can lead to a shorter time period for drug development.

Leading UK antibody players include Cambridge Antibody Technology (CAT), Celltech and Antisoma (ASM), while the strongest UK vaccine companies are Powderject, Acambis (ACM) and Oxford Biomedica (OXB)."